Nachrichten Oct 01, 2020

Protalix BioTherapeutics’ $30 Million At-The-Market Program

Shearman & Sterling represented BofA Securities, Inc. as sales agent in connection with the commencement of Protalix BioTherapeuitcs, Inc.’s at-the-market equity program to sell shares of its common stock, having an aggregate offering price of up to $30 million.

Protalix is a biopharmaceutical company based in Israel focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell based expression system.  In addition, Protalix’s development pipeline consists of other proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets.

The Team